eGenesis
E661990
eGenesis is a biotechnology company focused on using advanced gene-editing technologies to make animal organs safe and suitable for human transplantation.
All labels observed (1)
| Label | Occurrences |
|---|---|
| eGenesis canonical | 1 |
Statements (44)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| addressesProblem |
global shortage of transplantable human organs
ⓘ
immune rejection of xenotransplant organs ⓘ risk of cross-species viral transmission in xenotransplantation ⓘ |
| aim |
address organ shortage for human transplantation
ⓘ
eliminate porcine endogenous retroviruses from donor organs ⓘ reduce risk of organ rejection in xenotransplantation ⓘ |
| businessModel |
preclinical and clinical-stage biotech
ⓘ
therapeutic development ⓘ |
| collaboratesWith | academic medical centers for xenotransplantation research ⓘ |
| countryOfOrigin |
United States of America
ⓘ
surface form:
United States
|
| field |
gene editing
ⓘ
xenotransplantation ⓘ |
| focus |
developing xenotransplantation therapies
ⓘ
engineering donor animals for organ transplantation ⓘ making animal organs safe for human transplantation ⓘ |
| foundedBy |
George Church
NERFINISHED
ⓘ
Luhan Yang NERFINISHED ⓘ |
| foundedIn | 2015 ⓘ |
| hasEthicalConcernArea |
animal welfare in xenotransplantation
ⓘ
biosecurity of genetically modified animals ⓘ |
| hasFounderRole |
George Church is a co-founder of eGenesis
NERFINISHED
ⓘ
Luhan Yang is a co-founder of eGenesis NERFINISHED ⓘ |
| hasKeyPerson |
George Church
NERFINISHED
ⓘ
Luhan Yang NERFINISHED ⓘ |
| hasWebsite | https://www.egenesisbio.com/ ⓘ |
| headquartersLocation | Cambridge, Massachusetts, United States NERFINISHED ⓘ |
| industry | biotechnology ⓘ |
| productType |
genetically engineered donor organs
ⓘ
genetically modified pigs for organ donation ⓘ |
| regulatoryInteraction | works with regulators on xenotransplantation guidelines ⓘ |
| researchArea |
immunological compatibility between animal organs and humans
ⓘ
porcine-to-human organ transplantation ⓘ viral safety of xenotransplant organs ⓘ |
| scientificApproach |
insertion of human transgenes into donor animals
ⓘ
knockout of immunogenic pig genes ⓘ multiplex gene editing in pigs ⓘ |
| stage | clinical development in xenotransplantation ⓘ |
| targetPatientGroup | patients with end-stage organ failure ⓘ |
| usesTechnology |
CRISPR-based gene editing
ⓘ
advanced gene-editing technologies ⓘ |
| worksOnOrganType |
heart xenotransplantation
ⓘ
kidney xenotransplantation ⓘ liver xenotransplantation ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.